You are here

  • Home
  • Archive
  • Volume 10, Issue 1
  • Interstitial lung disease following COVID-19 vaccination: a disproportionality analysis using the Global Scale Pharmacovigilance Database (VigiBase)

Article info

Article menu
Interstitial lung disease
Interstitial lung disease following COVID-19 vaccination: a disproportionality analysis using the Global Scale Pharmacovigilance Database (VigiBase)

Authors

  • Min-Taek Lee College of Pharmacy, Chung-Ang University, Seoul, KoreaDepartment of Global Innovative Drugs, The Graduate School of Chung-Ang University, Seoul, Korea PubMed articlesGoogle scholar articles
  • Ju Won Lee College of Pharmacy, Chung-Ang University, Seoul, KoreaDepartment of Global Innovative Drugs, The Graduate School of Chung-Ang University, Seoul, Korea PubMed articlesGoogle scholar articles
  • Hyeon Ji Lee College of Pharmacy, Chung-Ang University, Seoul, KoreaDepartment of Global Innovative Drugs, The Graduate School of Chung-Ang University, Seoul, Korea PubMed articlesGoogle scholar articles
  • Jong-Min Lee College of Pharmacy, Chung-Ang University, Seoul, KoreaDepartment of Global Innovative Drugs, The Graduate School of Chung-Ang University, Seoul, Korea PubMed articlesGoogle scholar articles
  • Jae Chol Choi Division of Pulmonary and Allergy Medicine, Department of Internal Medicine, Chung-Ang University Gwangmyeong Hospital, Gwangmyeong-si, Gyeonggi-do, KoreaDepartment of Internal Medicine, Chung-Ang University College of Medicine, Seoul, South Korea PubMed articlesGoogle scholar articles
  • Kang-Mo Gu Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, South KoreaDivision of Pulmonary and Allergy Medicine, Department of Internal Medicine, Chung-Ang University Hospital, Seoul, Korea PubMed articlesGoogle scholar articles
  • Sun-Young Jung College of Pharmacy, Chung-Ang University, Seoul, Korea PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Sun-Young Jung; jsyoung{at}cau.ac.kr
View Full Text

Citation

Lee M, Lee JW, Lee HJ, et al
Interstitial lung disease following COVID-19 vaccination: a disproportionality analysis using the Global Scale Pharmacovigilance Database (VigiBase)
BMJ Open Respiratory Research 2023;10:e001992. doi: 10.1136/bmjresp-2023-001992

Publication history

  • Received July 31, 2023
  • Accepted November 14, 2023
  • First published December 11, 2023.
Online issue publication 
December 11, 2023

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.